SCHEDULE: FMR LLC Reports 8.8% Stake in Charles River Labs

FMR LLC and Abigail P. Johnson have jointly filed a Schedule 13G, disclosing beneficial ownership of 4,239,751.47 shares, representing 8.8% of Charles River Laboratories International, Inc.'s common stock as of June 30, 2026.

Summary

• FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting their beneficial ownership of Charles River Laboratories International, Inc. common stock.
• As of June 30, 2026, the total number of shares beneficially owned is 4,239,751.47.
• This holding represents 8.8% of the class of securities.
• FMR LLC holds sole voting power for 4,190,715.80 shares and sole dispositive power for 4,239,751.47 shares.
• Abigail P. Johnson has sole dispositive power for 4,239,751.47 shares.
• The filing indicates that other persons have the right to receive or direct the sale of these securities, but no single other person holds more than 5%.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily indicating a significant but stable institutional ownership stake without immediate strategic shifts.

Positives

• FMR LLC and Abigail P. Johnson maintain a significant ownership stake (8.8%) in Charles River Laboratories, indicating continued institutional confidence.
• The filing confirms substantial sole dispositive power for the reporting persons, suggesting control over their investment decisions.

Negatives

• The filing does not provide new strategic information or performance data, making it a routine disclosure of ownership.

Risks

• While not explicitly stated as a risk in this filing, significant institutional ownership can sometimes lead to increased pressure on management for short-term performance.
• Changes in the investment strategy of FMR LLC or Abigail P. Johnson could lead to substantial selling pressure on the stock.

Future Outlook

This filing is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• "This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the 'FMR Reporters')."
• "This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998)."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for large institutional investors like FMR LLC. This filing indicates a significant, stable holding in the contract research organization (CRO) sector, where Charles River Laboratories operates.

Comparison to Industry Standards

• As a Schedule 13G filing, it primarily reports ownership percentages. Direct comparison to industry performance benchmarks is not applicable.
• However, an 8.8% stake is a substantial holding for an institutional investor in the CRO industry, often indicating a long-term investment perspective.

Stakeholder Impact

• Shareholders: The continued significant ownership by FMR LLC may provide a degree of stability to the stock price, but also implies potential for future sales if their investment strategy changes.
• Management: The substantial stake held by FMR LLC may influence management decisions and strategic direction, particularly concerning corporate governance and long-term value creation.

Next Steps

• FMR LLC and Abigail P. Johnson will continue to monitor their beneficial ownership of Charles River Laboratories' common stock.
• Future amendments to this Schedule 13G will be filed if changes in beneficial ownership meet reporting thresholds.

Key Dates

Keywords

Charles River Laboratories, FMR LLC, Abigail P. Johnson, Schedule 13G, Institutional Ownership, Beneficial Ownership, Common Stock, Investment Management